US 10,519,222 B2 · Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region

Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region

AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, The Trustees of Columbia University in the City of New York, Centre for the AIDS Programme of Research in South Africa, University of the Witwatersrand, Johannesburg, National Health Laboratory Service

InventorsChaim Aryeh Schramm, Jason Gorman, John Mascola, Lawrence Stewart Shapiro, Lynn Morris, Nicole Amy Doria-Rose, Penelope Linda Moore, Peter Dak Pin Kwong, Salim Safurdeen Abdool Karim

Life of this patent

Estimating the term…

Abstract

The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.

Claims10

Dependent claims

An isolated anti-HIV-1 antibody which binds to V1V2, wherein the antibody includes a heavy chain with a CDR1 comprising the amino acids at positions 31-35 of SEQ ID NO:172, a CDR2 comprising the amino acids at positions 50-66 of SEQ ID NO:172, and a CDR3 comprising the amino acids at positions 99-134 of SEQ ID NO:172, and a light chain with a CDR1 comprising the amino acids at positions 23-35 of SEQ ID NO:173, a CDR2 comprising the amino acids at positions 51-57 of SEQ ID NO:173, and a CDR3 comprising the amino acids at positions 90-101 of SEQ ID NO:173.

Dependencies are inferred from the claim text.

Facts

Application

15/121,051Filed 27 Feb 2015

Priority

GB 1403613.128 Feb 2014

Published

US 2016/0362479 A115 Dec 2016

Granted

31 Dec 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 16/1145
Lentivirus , e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]: env proteins,…
A61K 39/42
Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum: viral
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 31/18
For RNA viruses: for HIV